Immunexpress to Present Data on SeptiCyte® at the "Meeting of Experts on Biomarkers to Discriminate Bacterial from Other Infectious Causes of Acute Fever"

SEATTLE, Sept. 16, 2015 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, announced today that Dr. Therese Seldon, Vice President of Operations, will present data on SeptiCyte® technology at the "Meeting of Experts on Biomarkers to Discriminate Bacterial from Other Infectious Causes of Acute Fever" on Sept. 22 in Geneva, Switzerland.

• Oral presentation: "Re-defining Sepsis Using the Host Immune Response"
  Session: The Industry Landscape
  Presenter: Dr. Therese Seldon
  Date: Tuesday, Sept. 22
  Time: 11 a.m. CEST

The event is co-hosted by the World Health Organization, the Foundation for Innovative New Diagnostics, the Médecins Sans Frontières Access Campaign and ReAct - Action on Antibiotic Resistance. The meeting aims to bring together experts on biomarkers to distinguish bacterial from non-bacterial infections in order to guide the development of low-cost diagnostic technologies.

Sepsis is a life-threatening condition that arises when the body's response to infection damages its own tissues and organs. Sepsis diagnostics today aim to identify the pathogen only and therefore have serious limitations in respect of speed and sensitivity. The Immunexpress SeptiCyte® solution evaluates the host immune response to aid clinicians in quickly and accurately diagnosing sepsis.

About Immunexpress

Immunexpress is a Seattle-based molecular diagnostic company committed to improving outcomes for patients with, or at risk of, sepsis. Immunexpress's SeptiCyte^® technology quantifies directly from whole blood specific molecular markers from the patient's own immune system – the "host response." Detecting the host's septic immune response can diagnose sepsis earlier and more accurately than current sepsis diagnostics that focus on identifying the invading pathogen. Immunexpress's pipeline includes monitoring assays for readily available platforms, including point-of-care (POC) sample-to-answer platforms. For more information visit www.Immunexpress.com.

Follow Immunexpress on Twitter at twitter.com/Immunexpress and LinkedIn at www.linkedin.com/company/immunexpress-inc.

Media Contacts:
David Schull or Todd Davenport, Ph.D.
Russo Partners
(212) 845-4271
(212) 845-4262
[email protected]
[email protected]

SOURCE Immunexpress, Inc.

Related Links

http://www.Immunexpress.com